Trials / Completed
CompletedNCT01276691
Effect of Aspirin on Hemostatic and Vascular Function After Live Fire Fighting
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- University of Illinois at Urbana-Champaign · Academic / Other
- Sex
- Male
- Age
- 40 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
The investigators hypothesize that 1. an acute treatment of low-dose aspirin will lead to a) decreased resting platelet activation, platelet aggregation, and clotting potential, b) increased fibrinolytic potential following fire fighting, c) no significant effect on endothelial function or arterial stiffness versus the placebo condition. 2. chronic treatment with low-dose aspirin will lead to a) decreased resting and fire fighting induced platelet activation, platelet aggregation, clotting potential, b) increased fibrinolytic potential, and c) increased endothelial function and decreased arterial stiffness in response to live fire fighting versus the placebo condition. 3. short-term fire fighting activity will result in: a) a reduction in arterial function (reduced endothelial function, increased augmentation index and an attenuated arterial stiffness response); b) a disruption in hemostasis that is characterized by an increase in platelet number and function, an increased coagulatory potential and altered fibrinolytic potential; and c) an elevation in procoagulatory cytokines, systemic inflammation, monokine chemoattractant protein, and matrix metalloproteinases.
Conditions
- Cardiovascular Risk Factor
- C.Medical Procedure; Vascular, Functional or Late
- Electrolyte and Fluid Balance Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 81 mg enteric coated aspirin | 81 mg enteric coated aspirin will be provided both as an acute dosage immediately prior to firefighting (1 hour pre-activity) and as a 14 day dosage prior to firefighting |
Timeline
- Start date
- 2011-02-01
- Primary completion
- 2011-10-01
- Completion
- 2012-12-01
- First posted
- 2011-01-13
- Last updated
- 2020-07-21
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01276691. Inclusion in this directory is not an endorsement.